Trial Profile
Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Nivolumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Status changed from active, no longer recruiting to discontinued, as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Sep 2023 Planned End Date changed from 27 Mar 2024 to 22 Sep 2024.